Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImageneBio ( (IMA) ) just unveiled an update.
On December 12, 2025, ImageneBio announced that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., had submitted her resignation, effective December 31, 2025, with the company noting that her departure did not stem from any disagreement over operations, policies, or practices. ImageneBio has begun searching for a new Chief Medical Officer and expects Dr. Lu to remain involved by providing transition advisory services after her resignation to support continuity in its medical and clinical functions.
The most recent analyst rating on (IMA) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on ImageneBio stock, see the IMA Stock Forecast page.
Spark’s Take on IMA Stock
According to Spark, TipRanks’ AI Analyst, IMA is a Neutral.
Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.
To see Spark’s full report on IMA stock, click here.
More about ImageneBio
Average Trading Volume: 70,072
Technical Sentiment Signal: Sell
Current Market Cap: $73.2M
See more insights into IMA stock on TipRanks’ Stock Analysis page.